ArticleInternational journal of surgery case reports2025
Utilization of dupilumab in an immunocompromised patient with extensive allergic fungal rhinosinusitis unsuitable for surgical intervention: A case report.
Article in International journal of surgery case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAllergic fungal rhinosinusitis (AFRS) is a distinct subset of chronic rhinosinusitis characterized by a type I hypersensitivity to fungi. Immunocompromised patients are at increased risk for fungal infections. This case highlights the complexities of managing AFRS in patients not eligible for surgery. CASE PRESENTATION: We present a 32-year-old patient with a history of Wilson's disease and a previous liver transplant on immunosuppressive medications. The patient presented to our tertiary hospital with a year-long history of bilateral progressive nasal obstruction, along with diplopia, anterior and posterior rhinorrhea, intermittent numbness on the left side of her face, tinnitus and nausea. Initial imaging revealed extensive sinonasal disease with hyperdense components. FESS was performed, and biopsy and culture confirmed the diagnosis of AFRS. Notably, gross dehiscence of the carotid arteries was observed during surgery. Three and a half years after surgery, the patient experienced a relapse of symptoms after COVID-19 infection. Due to the risk of inadvertent damage to the carotid artery during surgery, the patient was offered a trial of dupilumab instead. The patient reported complete resolution of symptoms 6 months after starting dupilumab. DISCUSSION: Given the significant surgical risks associated with carotid artery dehiscence, a trial of dupilumab was initiated. This biologic therapy, known for its efficacy in treating type 2 inflammatory conditions, resulted in a remarkable response, with complete resolution of symptoms within six months. Previous reports of dupilumab use in AFRS have yielded similar outcomes.
conclusionThe case underscores the potential of dupilumab as a safe and effective alternative for managing recalcitrant AFRS, particularly in patients at high risk for surgical complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.